Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

AXATILIMAB vs VIMSELTINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

AXATILIMAB vs VIMSELTINIB: Safety Overview

Metric AXATILIMAB VIMSELTINIB
Total FAERS Reports 16 170
Deaths Reported 2 0
Death Rate 12.5% N/A
Hospitalizations 13 5
Average Patient Age 39.6 yrs 45.6 yrs
% Female Patients 61.1% 55.4%
FDA Approval Date N/A Feb 14, 2025
Manufacturer Incyte Corporation Deciphera Pharmaceuticals, LLC
Route INTRAVENOUS ORAL
Marketing Status N/A Prescription